CP 471474 inhibits MMPs, enzymes that degrade extracellular matrix components, thus having potential therapeutic applications in cancer and chronic inflammatory diseases. It targets MMP-1, MMP-13, MMP-2, MMP-3, and MMP-9.
CP 471474 is studied to evaluate its potential in treating diseases involving excessive degradation of extracellular matrix proteins, like cancer and fibrosis.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.